PLEASANTON, Calif., Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument revenue, offset by stronger contributions from consumables. Began shipping GEM-X Flex, sett ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications. These launches are part of the company's str ...

● ● . Torex Gold Reports Q3 2024 Production Results Solidly on track to deliver full-year production guidance following strong third quarter results October 08, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - October 8, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q3 2024 gold production of 119,412 ounces ("oz") and gold sold of 122,130 oz. With year-to-date gold production of 348,728 oz, the Company is on track to achieve annual go ...

● . ● Torex Gold Welcomes the Addition of a New Director Caroline Donally brings extensive mining sector experience in commerce and financial markets September 23, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to announce the addition of Caroline Donally CA(SA) to its Board of Directors ("the Board") effective October 1, 2024. Rick Howes, Chair of the Board, stated: "Ca ...

In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach. PLEASANTON, Calif., Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and Xenium In Situ platforms were used in a publication – featured on the cover of Cancer Ce ...

● . ● Torex Gold Integrates EPO Deposit into Morelos Mine Plan Updated mine plan shows a robust long-term production profile that comes with a low risk, capital efficient development plan for EPO September 04, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc. (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports an updated life-of-mine plan for the Morelos Complex whi ...

Toronto, Ontario--(Newsfile Corp. - August 29, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces that on the morning of August 29th, a fatal injury occurred involving a contract worker within the Guajes Tunnel. Jody Kuzenko, President & CEO of Torex, stated: "We are deeply saddened by the death of a 40-year-old male contractor who suffered fatal injuries while working in the Guajes Tunnel and our thoughts are with his family and friends. Our full support is being provided to ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $153 million, representing a 4% year-over-year growth and a 9% quarter-over-quarter increase [4][20] - Total consumables revenue was $123.4 million, up 10% year-over-year, while spatial consumables revenue surged 150% to $29.3 million [21] - Instrument revenue decreased by 23% to $23.9 million, with Chromium instrument revenue down 32% year-over-year [22][23] - Gross profit for Q2 was $104.2 million, with a gross margin of 68%, unchanged from the previous year [23][24] - Net loss for the period was $37.9 million, an improvement from a net loss of $62.4 million in Q2 2023 [25] Business Line Data and Key Metrics Changes - Spatial consumables growth was driven by Visium HD and the newly launched Xenium Prime 5K product [5][21] - Chromium consumables revenue was $94.1 million, down 7% year-over-year, but showed a 12% sequential increase [21] - Instrument sales, particularly for Xenium, faced challenges due to macroeconomic pressures and elongated purchase cycles [5][22] Market Data and Key Metrics Changes - Revenue in the Americas grew 2% to $93.1 million, while EMEA revenue increased by 20% to $37.4 million; APAC revenue decreased by 6% to $22.7 million [23] - The company noted a strong demand for spatial consumables, particularly in the EMEA region, which contributed to overall growth [23][64] Company Strategy and Development Direction - The company is focused on driving down costs per sample and per cell to enhance accessibility for researchers [15][73] - A new Chief Commercial Officer has been appointed to lead a restructuring aimed at improving commercial execution and addressing recent challenges [16][17] - The company plans to leverage its technology leadership and extensive commercial channels to maintain a competitive edge in the market [6][7] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing macroeconomic headwinds affecting customer budgets and capital expenditures, which are expected to persist [5][25] - Despite near-term challenges, the company remains confident in its long-term growth potential and the strength of its platforms [6][26] - The updated revenue guidance for 2024 is now projected to be between $640 million and $660 million, reflecting the impact of macroeconomic factors and commercial restructuring [25][26] Other Important Information - The company reported being free cash flow positive in Q2 2024, ending the quarter with $380.1 million in cash and cash equivalents [25] - The transition to the GEM-X product line is progressing faster than anticipated, with expectations of increased adoption in the future [12][38] Q&A Session Summary Question: Can you add color to the forecast for the second half of the year? - The updated guidance is primarily due to macroeconomic factors affecting capital expenditures, particularly for Xenium instruments, and the impact of commercial restructuring [28][29] Question: Can you share insights on ASP trends for Xenium? - ASP for Xenium has remained stable, with no major changes, although customers are opting for lower-priced options due to budget constraints [34] Question: What is the impact of the GEM-X transition in the quarter? - The GEM-X transition is progressing as expected, with a longer tail effect anticipated as customers adapt to the new product [37][38] Question: How are Xenium placements expected to trend for the rest of the year? - Xenium placements are being impacted by macroeconomic conditions, leading to elongated sales cycles and budget scrutiny [40][41] Question: What drove the strong revenue growth in China and EMEA? - Improved visibility and restructuring of distributor relationships contributed to better performance in China, while EMEA growth was driven by strong demand for consumables [63]

For the quarter ended June 2024, 10x Genomics (TXG) reported revenue of $153.1 million, up 4.3% over the same period last year. EPS came in at -$0.32, compared to -$0.53 in the year-ago quarter. The reported revenue represents a surprise of +1.46% over the Zacks Consensus Estimate of $150.9 million. With the consensus EPS estimate being -$0.47, the EPS surprise was +31.91%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

10x Genomics (TXG) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 31.91%. A quarter ago, it was expected that this life science technology company would post a loss of $0.46 per share when it actually produced a loss of $0.50, delivering a surprise of -8.70%. Over the last four quarters, th ...